Eurofins Discovery provides a wide range of services to identify and screen for cardiovascular-targeted therapies, as well as to de-risk candidates for cardiac safety liabilities. With our diverse portfolio, you can confidentially advance small and large molecule programs targeting inflammation, blood lipid levels, and thrombosis—in addition to the traditional GPCR and ion channel targets.
Our recognized expertise in this area combined with the global need to de-risk development candidates from cardiac liability established our participation in the US Food and Drug Administration’s (US FDA) Consortium for Comprehensive in vitro Proarrythmia Assay (CiPA) Initiative. As a benefit to clients looking to easily assess the proarrhythmic risk of new drugs with confidence, ion channel assays recommended by the CiPA Initiative and regulatory agencies are conveniently grouped into our CiPA Panel Profiling Service.
No matter where you are in your preclinical discovery or development, we have human model systems and solutions – primary and induced pluripotent stem cell (iPSC) – to advance your cardiovascular disease programs.
Efficacy Determinations
- Identify potent and selective leads from the largest source of off-the-shelf GPCR and Ion Channel assays, readily available in high-throughput platforms
- Correlate biomarker readout activity with chemical structures and informatics for structure-activity-relationship (SAR) determinations
- Benchmark for efficacy (and safety) against a library of clinically-approved (and withdrawn) drugs
Safety Determinations
- Detect proarrhythmia liabilities with our comprehensive CiPA Panel
- Predict thrombosis and cardiovascular toxicity potential with primary cell-based disease models with our BioMAP® Toxicity Signature Analysis
- Assess the risk of delayed ventricular repolarization and QT interval prolongation with our iPSC-derived Cardiomyocyte Calcium Transient Assays
- Determine the risk of drug-induced ion channel blockade with our iPSC Multielectrode Array (MEA) Assays
